Gemfibrozil greatly increases plasma concentrations of cerivastatin.
about
Optimal lipid modification: the rationale for combination therapyFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewRole of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsExamination of 209 drugs for inhibition of cytochrome P450 2C8An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic studyThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysisImpact of OATP transporters on pharmacokinetics.Cerivastatin, genetic variants, and the risk of rhabdomyolysis.Cytochrome P450 2C8 pharmacogenetics: a review of clinical studiesPharmacogenetics in drug regulation: promise, potential and pitfalls.CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsLack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.Statins: past and present.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media.Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.Fibrates in combination with statins in the management of dyslipidemia.Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Can pharmacogenetics help rescue drugs withdrawn from the market?Transporter-mediated drug interactions: clinical implications and in vitro assessment.Cytochrome P450 reaction-phenotyping: an industrial perspective.Pitavastatin: efficacy and safety in intensive lipid lowering.Transporter-mediated uptake into cellular compartments.Role of OATP transporters in the disposition of drugs.Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrelInterindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexOATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
P2860
Q28219266-E9FF2578-AFB2-470D-B154-E1ED6DF607F9Q28220294-AEFCC5AC-BA2A-47D3-B4AA-2A71FF672442Q28236180-C35C309E-3B6E-4996-B2AA-97EECDA0823AQ28298519-54EB90AF-BA8D-4210-81B5-5FE151D67F9CQ31123470-490A3040-8E06-432F-A36B-A1088C72C6ACQ33746585-2976B76F-D7C6-423B-9CA8-A76188235E36Q34276618-0EFAADBE-6F95-48C9-BD68-E46C90238D3AQ34360732-3D9AC996-CB7A-460D-B701-E988B885D332Q34612244-79FEDDAE-3209-45F6-B80F-3FFA237945D7Q34792178-69DF2BE1-1090-4310-8CC2-455860141AEAQ35003605-7E3C298B-0E13-421A-839D-3230936EAE01Q35038052-69209057-0643-4AFF-BA3E-2EC98616EC90Q35718619-3F62B721-1F97-480B-8626-12AE27FCFEC1Q35826014-61E2B98B-3D63-4768-9D98-2853D99E61A3Q35826433-88365B01-7A30-4496-A89B-42DBCA21F68BQ35826894-94A7D1E9-13F4-45A7-B144-BBC93829B466Q35827146-733B6D90-BA94-4210-A6ED-1B1C5F97CA79Q35827269-B460A0A8-9B21-4D96-8645-8E72F49DF125Q35936339-0E4A24F6-4E35-4EAC-B37A-534FDA0AA62FQ36040772-679036DA-0FCA-47E3-BC35-3630682DAA50Q36163801-4FDAA40F-4C7B-47C3-AFBE-33B23C333239Q36320218-C1A2B5C2-E054-4A03-B355-132D061E5AD1Q36349758-2B1C70EF-7364-45F4-9FFB-CC769741F3F6Q36366283-965B5164-76EF-47FF-861E-D41DF6BE546DQ36544962-B4C7A1C4-DD86-4A5B-97BC-DDFEC7224447Q36544966-3EE3A632-462B-4E04-B5BC-550C711A7337Q36562502-53EBDD11-0451-44BE-B6BF-4E79D3B25BC3Q36596713-CF2D8A6E-4F0A-4A8E-84BF-DC5FFEC7ED09Q36725222-B50EFA97-EFD2-4BBA-9720-6C38AE44FD81Q36960539-0FDD1B48-5E4C-4BA4-9A91-2FDDA3E50DD7Q36967274-16B3F4F8-588F-4D84-81E0-B966F18F21DAQ36985076-4EF8D220-C864-4CD8-86B2-46E80E129831Q37074085-5D354264-112A-4229-8C60-00EA72303AFEQ37114391-E89DA6C7-D841-4BF0-B4E7-E56078D9ADF0Q37124261-AFEE8FDA-6D21-427A-96C9-D993942E954AQ37196109-6ED3D649-4AC0-4C27-9174-6A330BE32ECFQ37237438-986C1881-B5AA-4404-AB9C-BCDEB1FCFAD5Q37316562-BEA9075E-7BCF-4665-AB54-656A912ED396Q37422685-A99D7C32-42A4-4D76-80EE-AF47E6FFF389Q37489569-B2679119-4547-455E-A1BF-A0F35AD4DC4B
P2860
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@ast
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@en
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@nl
type
label
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@ast
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@en
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@nl
prefLabel
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@ast
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@en
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@nl
P2093
P356
P1476
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
@en
P2093
Carl Kyrklund
Janne T Backman
Pertti J Neuvonen
P304
P356
10.1067/MCP.2002.128469
P407
P577
2002-12-01T00:00:00Z